Hims & Hers Health, Inc. (HIMS) Guidance & Earnings Results

On 2026-08-10 Hims & Hers Health, Inc. raised guidance: "FY2026 revenue raised to $3.1-3.3B; Q3 2026 revenue $880-900M; FY2026 Adjusted EBITDA $275-325M; Q3 2026 Adjusted EBITDA…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HIMSHims & Hers Health, Inc.Follow HIMS — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 6.5B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 9 Nov, in 16 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
10 Aug 26	Raised	FY2026 revenue raised to $3.1-3.3B; Q3 2026 revenue $880-900M; FY2026 Adjusted EBITDA $275-325M; Q3 2026 Adjusted EBITDA $75-95M · full year
11 May 26	Raised	FY2026 revenue guidance raised to $2.8B-$3.0B; Adjusted EBITDA $275M-$350M · full year
23 Feb 26	Raised	FY2026 revenue $2.7B-$2.9B, Adjusted EBITDA $300M-$375M · full year
3 Nov 25	Raised	FY2025 revenue guidance narrowed to $2.335B-$2.355B, EBITDA to $307M-$317M · full year
4 Aug 25	Reaffirmed	FY2025 revenue $2.3B-$2.4B; FY2025 Adjusted EBITDA $295M-$335M (margin 13%-14%); Q3 2025 revenue $570M-$590M; Q3 2025 Adjusted EBITDA $60M-$70M (margin 11%-12%) · full year

Hims & Hers Health, Inc. — questions

What guidance did Hims & Hers Health, Inc. give?: On 2026-08-10: "FY2026 revenue raised to $3.1-3.3B; Q3 2026 revenue $880-900M; FY2026 Adjusted EBITDA $275-325M; Q3 2026 Adjusted EBITDA $75-95M"
When does Hims & Hers Health, Inc. report earnings?: Hims & Hers Health, Inc.'s next earnings report is expected on 2026-11-09.

Every figure on this page comes from Hims & Hers Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.